Switching to aspirin/clopidogrel following 1 month of new P2Y12 inhibitor/aspirin post-ACS

Paris, France: Switching to a fixed-dose combination of aspirin plus clopidogrel after one month of potent dual antiplatelet therapy (DAPT) with a new P2Y12 inhibitor plus aspirin following an acute coronary syndrome (ACS) treated with a percutaneous coronary intervention (PCI) is associated with reduced risk of bleeding complications with no increase in ischaemic events, showed results from a study reported at EuroPCR 2017.
Go to Source